Home
Companies
BeOne Medicines

BeOne Medicines

Company

Also known as: BeOne Medicines

Company Profile

BeOne Medicines is a global oncology company developing and delivering cancer medicines across multiple markets. Founded in 2010 and now based in Basel, it operates as a publicly listed company with broad international R&D and commercialization activity.

Website: https://beonemedicines.com
Headquarters: Basel, Switzerland
Founded: 2010
Stock Ticker: NASDAQ:ONC

Related News

Oncology Drug Market Sees Strong Growth Amid Patent Cliffs and Novel Modality Shifts

Jun 05, 2026

Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.

Orphan Drug Market Projected to Reach $409 Billion by 2032, Driven by Rare Disease Treatments

Mar 17, 2026

Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.

Zanubrutinib Shows Superior Efficacy and Persistence Over Other BTK Inhibitors in CLL and B-Cell Lymphomas

Mar 11, 2026

Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07590102	A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants	NOT_YET_RECRUITING	PHASE1
NCT07554521	A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States	RECRUITING	PHASE2
NCT07492641	BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease	RECRUITING	PHASE3
NCT07485049	BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors	RECRUITING	EARLY_PHASE1
NCT07414836	A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors	RECRUITING	PHASE1
NCT07341191	Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy	RECRUITING	PHASE2
NCT07277231	A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia	RECRUITING	PHASE3
NCT07226349	A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors	RECRUITING	PHASE1
NCT07222267	An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors	RECRUITING	PHASE1
NCT07181681	A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors	RECRUITING	PHASE1